JOURNEY MEDICAL CORP (DERM) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:DERM • US48115J1097

8.35 USD
0 (0%)
At close: Feb 6, 2026
8.35 USD
0 (0%)
After Hours: 2/6/2026, 8:28:34 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall DERM gets a fundamental rating of 3 out of 10. We evaluated DERM against 191 industry peers in the Pharmaceuticals industry. DERM may be in some trouble as it scores bad on both profitability and health. DERM is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

  • In the past year DERM has reported negative net income.
  • DERM had a negative operating cash flow in the past year.
  • In the past 5 years DERM reported 4 times negative net income.
  • The reported operating cash flow has been mixed in the past 5 years: DERM reported negative operating cash flow in multiple years.
DERM Yearly Net Income VS EBIT VS OCF VS FCFDERM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • DERM's Return On Assets of -10.17% is fine compared to the rest of the industry. DERM outperforms 67.02% of its industry peers.
  • DERM has a Return On Equity of -33.45%. This is in the better half of the industry: DERM outperforms 60.21% of its industry peers.
Industry RankSector Rank
ROA -10.17%
ROE -33.45%
ROIC N/A
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
DERM Yearly ROA, ROE, ROICDERM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K 2K

1.3 Margins

  • Looking at the Gross Margin, with a value of 64.40%, DERM is in the better half of the industry, outperforming 73.30% of the companies in the same industry.
  • In the last couple of years the Gross Margin of DERM has declined.
  • The Profit Margin and Operating Margin are not available for DERM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 64.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
DERM Yearly Profit, Operating, Gross MarginsDERM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

1

2. Health

2.1 Basic Checks

  • DERM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, DERM has more shares outstanding
  • The number of shares outstanding for DERM has been increased compared to 5 years ago.
  • The debt/assets ratio for DERM is higher compared to a year ago.
DERM Yearly Shares OutstandingDERM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
DERM Yearly Total Debt VS Total AssetsDERM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of 0.73, we must say that DERM is in the distress zone and has some risk of bankruptcy.
  • DERM has a Altman-Z score of 0.73. This is comparable to the rest of the industry: DERM outperforms 50.79% of its industry peers.
  • DERM has a Debt/Equity ratio of 0.75. This is a neutral value indicating DERM is somewhat dependend on debt financing.
  • Looking at the Debt to Equity ratio, with a value of 0.75, DERM is doing worse than 69.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Altman-Z 0.73
ROIC/WACCN/A
WACC9.63%
DERM Yearly LT Debt VS Equity VS FCFDERM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M 300M

2.3 Liquidity

  • A Current Ratio of 1.42 indicates that DERM should not have too much problems paying its short term obligations.
  • Looking at the Current ratio, with a value of 1.42, DERM is doing worse than 71.73% of the companies in the same industry.
  • A Quick Ratio of 1.12 indicates that DERM should not have too much problems paying its short term obligations.
  • With a Quick ratio value of 1.12, DERM is not doing good in the industry: 75.92% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.42
Quick Ratio 1.12
DERM Yearly Current Assets VS Current LiabilitesDERM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 41.41% over the past year.
  • The Revenue has been growing slightly by 2.82% in the past year.
  • Measured over the past years, DERM shows a quite strong growth in Revenue. The Revenue has been growing by 9.96% on average per year.
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
Revenue 1Y (TTM)2.82%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.52%

3.2 Future

  • DERM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 48.50% yearly.
  • The Revenue is expected to grow by 39.53% on average over the next years. This is a very strong growth
EPS Next Y52%
EPS Next 2Y50.08%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue Next Year13.98%
Revenue Next 2Y33.27%
Revenue Next 3Y39.53%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
DERM Yearly Revenue VS EstimatesDERM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M 150M
DERM Yearly EPS VS EstimatesDERM Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • DERM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • A Price/Forward Earnings ratio of 32.42 indicates a quite expensive valuation of DERM.
  • DERM's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. DERM is cheaper than 72.77% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.78, DERM is valued at the same level.
Industry RankSector Rank
PE N/A
Fwd PE 32.42
DERM Price Earnings VS Forward Price EarningsDERM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DERM Per share dataDERM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

  • DERM's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as DERM's earnings are expected to grow with 48.50% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y50.08%
EPS Next 3Y48.5%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DERM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

JOURNEY MEDICAL CORP

NASDAQ:DERM (2/6/2026, 8:28:34 PM)

After market: 8.35 0 (0%)

8.35

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-19
Inst Owners40.23%
Inst Owner Change1.79%
Ins Owners15.49%
Ins Owner Change10.51%
Market Cap176.52M
Revenue(TTM)59.40M
Net Income(TTM)-8.66M
Analysts82
Price Target13.77 (64.91%)
Short Float %17.41%
Short Ratio17.9
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-67.58%
Min EPS beat(2)-85.76%
Max EPS beat(2)-49.39%
EPS beat(4)2
Avg EPS beat(4)-12.79%
Min EPS beat(4)-85.76%
Max EPS beat(4)58.28%
EPS beat(8)2
Avg EPS beat(8)-31.88%
EPS beat(12)4
Avg EPS beat(12)26.25%
EPS beat(16)5
Avg EPS beat(16)-0.28%
Revenue beat(2)0
Avg Revenue beat(2)-4.89%
Min Revenue beat(2)-8.32%
Max Revenue beat(2)-1.46%
Revenue beat(4)1
Avg Revenue beat(4)-2.25%
Min Revenue beat(4)-8.32%
Max Revenue beat(4)6.86%
Revenue beat(8)2
Avg Revenue beat(8)-1.81%
Revenue beat(12)4
Avg Revenue beat(12)5.69%
Revenue beat(16)5
Avg Revenue beat(16)1.83%
PT rev (1m)0%
PT rev (3m)12.5%
EPS NQ rev (1m)-27.78%
EPS NQ rev (3m)-243.75%
EPS NY rev (1m)-2.67%
EPS NY rev (3m)-52.38%
Revenue NQ rev (1m)-2.46%
Revenue NQ rev (3m)-16%
Revenue NY rev (1m)-0.73%
Revenue NY rev (3m)-6.88%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 32.42
P/S 2.97
P/FCF N/A
P/OCF N/A
P/B 6.82
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)0.26
Fwd EY3.08%
FCF(TTM)-0.9
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS2.81
BVpS1.23
TBVpS-0.13
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.17%
ROE -33.45%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 64.4%
FCFM N/A
ROA(3y)-17.17%
ROA(5y)-17.31%
ROE(3y)-88.97%
ROE(5y)-64.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.86%
GM growth 5Y-4.08%
F-Score5
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0.75
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.42
Quick Ratio 1.12
Altman-Z 0.73
F-Score5
WACC9.63%
ROIC/WACCN/A
Cap/Depr(3y)346.04%
Cap/Depr(5y)304.38%
Cap/Sales(3y)20.06%
Cap/Sales(5y)15.74%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.06%
EPS Next Y52%
EPS Next 2Y50.08%
EPS Next 3Y48.5%
EPS Next 5YN/A
Revenue 1Y (TTM)2.82%
Revenue growth 3Y-3.84%
Revenue growth 5Y9.96%
Sales Q2Q%20.52%
Revenue Next Year13.98%
Revenue Next 2Y33.27%
Revenue Next 3Y39.53%
Revenue Next 5YN/A
EBIT growth 1Y44.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year111.72%
EBIT Next 3Y84.38%
EBIT Next 5YN/A
FCF growth 1Y-246.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.93%
OCF growth 3YN/A
OCF growth 5YN/A

JOURNEY MEDICAL CORP / DERM FAQ

What is the ChartMill fundamental rating of JOURNEY MEDICAL CORP (DERM) stock?

ChartMill assigns a fundamental rating of 3 / 10 to DERM.


Can you provide the valuation status for JOURNEY MEDICAL CORP?

ChartMill assigns a valuation rating of 3 / 10 to JOURNEY MEDICAL CORP (DERM). This can be considered as Overvalued.


What is the profitability of DERM stock?

JOURNEY MEDICAL CORP (DERM) has a profitability rating of 2 / 10.